Role of gastroesophageal reflux disease in lung transplantation

Table 2 Papers on the effect of pharmacologic reflux treatment on transplant outcome

Ref.	n	Population	Treatment type	Adjunctive treatments	Outcomes assessed
Yates et al[32], 2005	20	Post-LTx with diagnosis of BOS (n = 18) or potential BOS (n = 2)	AZI 250 mg QOD from time of BOS diagnosis to time of manuscript writing (mean 6.25 mo)	Immunosuppressive regimen, no additional antireflux agents specified	Effect on FEV1
Verleden et al[110], 2004	8	Post-LTx with significant decrease in their FEV1 attributed to BOS	AZI 250 mg qd × 5 d then 250 mg po QOD	Immunosuppressive regimen, no additional antireflux agents specified	Effect on FEV1
Verleden et al[111], 2006	14	Post-LTx with BOS	AZI 250 mg po qd × 5 d then AZI 250 mg po 3 × /wk × 3 mo	Immunosuppressive regimen, no additional antireflux agents specified	Reduction in airway neutrophilia and IL-8 mRNA, effect on FEV1
Mertens et al[112], 2009	12	Post-LTx on AZI with pH monitoring	AZI 250 mg PO 3 ×/wk	Immunosuppressive regimen, held antireflux treatments × 1 wk prior to testing	Effect on impedance-pH monitoring, gastric aspiration via BAL analysis
Blondeau et al[78], 2008	18	Post-LTx on PPI vs off PPI at time of testing (secondary cohort)	Omeprazole 20 mg PO BID	Immunosuppressive regimen	Prevalence of reflux on objective testing, effect on aspiration in BAL

n: Patients in the study in the treatment arm; BOS: Bronchiolitis obliterans syndrome; LTx: Lung transplant; AZI: Azithromycin; QOD: Every other day; FEV1: Forced expiratory volume in 1 s; BID: Twice a day.